JOP20130236B1 - تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha - Google Patents
تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alphaInfo
- Publication number
- JOP20130236B1 JOP20130236B1 JOP/2013/0236A JOP20130236A JOP20130236B1 JO P20130236 B1 JOP20130236 B1 JO P20130236B1 JO P20130236 A JOP20130236 A JO P20130236A JO P20130236 B1 JOP20130236 B1 JO P20130236B1
- Authority
- JO
- Jordan
- Prior art keywords
- inhibitor
- pharmaceutical formulations
- raf
- egfr
- formulations including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20130236B1 true JOP20130236B1 (ar) | 2021-08-17 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0236A JOP20130236B1 (ar) | 2012-08-07 | 2013-08-06 | تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha |
Country Status (39)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2882440T3 (da) * | 2012-08-07 | 2019-05-06 | Novartis Ag | Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor |
| UA118846C2 (uk) | 2013-03-21 | 2019-03-25 | Новартіс Аг | Комбінована терапія |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| EA201790019A1 (ru) * | 2014-06-16 | 2017-06-30 | Уорлдуайд Иновейтив Нетуорк | Способ выбора персонализированной трехкомпонентной терапии для лечения рака |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| US10328065B2 (en) | 2015-08-28 | 2019-06-25 | Novartis Ag | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
| JP2018526375A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | 組み合わせ療法 |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| PL3463345T3 (pl) | 2016-06-03 | 2023-02-06 | Array Biopharma Inc. | Kombinacje farmaceutyczne |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| BR112020001916A2 (pt) * | 2017-08-03 | 2020-07-28 | Novartis Ag | combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de raf |
| IL316875A (en) | 2018-10-05 | 2025-01-01 | Annapurna Bio Inc | Compounds and compositions for treating conditions associated with APJ receptor activity |
| TW202444718A (zh) * | 2019-01-25 | 2024-11-16 | 英屬開曼群島商百濟神州有限公司 | 作為ｂ－ｒａｆ激酶二聚體抑制劑之化合物及其製備方法 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| CN113795490A (zh) | 2019-05-13 | 2021-12-14 | 诺华股份有限公司 | N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症 |
| US20250108051A1 (en) * | 2022-01-27 | 2025-04-03 | Tohoku University | Therapeutic agent for cancer |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| AU2023351185A1 (en) * | 2022-09-26 | 2025-04-24 | Amgen Inc. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| RS52939B (sr) | 2007-04-10 | 2014-02-28 | Exelixis Inc. | Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| RU2553379C2 (ru) * | 2009-08-24 | 2015-06-10 | Дженентек, Инк. | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| BR112012008519A2 (pt) * | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combinação |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| BR112013009624A2 (pt) * | 2010-11-08 | 2016-07-12 | Novartis Ag | uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr |
| US20140275174A1 (en) | 2011-11-10 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| CA2855243C (en) * | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
| DK2882440T3 (da) * | 2012-08-07 | 2019-05-06 | Novartis Ag | Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor |
-
2013
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-04 PH PH12015500246A patent/PH12015500246B1/en unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20130236B1 (ar) | تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha | |
| MX2015001122A (es) | Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| EA201491614A1 (ru) | Способ лечения гинекологических заболеваний | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
| WO2014155268A3 (en) | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity | |
| EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы | |
| PL401282A1 (pl) | Zastosowanie inhibitorów proteaz cysteinowych jako czynnik hamujacy wzrost komórek nowotworowych |